A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards

Journal of the American Academy of Dermatology

Volumn 74, Issue 2, 2016, Pages 288-294

  Futamura, Masaki ^b   Leshem, Yael A ^c   Thomas, Kim S ^a   Nankervis, Helen ^a   Williams, Hywel C ^a   Simpson, Eric L ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

atopic dermatitis; atopic eczema; global assessment; Investigator Global Assessment; outcome measure; randomized controlled trial; severity; systematic review

Indexed keywords

ARTICLE; ATOPIC DERMATITIS; CLINICAL ASSESSMENT TOOL; DATA BASE; GEOGRAPHIC DISTRIBUTION; HUMAN; INVESTIGATOR GLOBAL ASSESSMENT; NOMENCLATURE; NORTH AMERICAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; STANDARDIZATION; SYSTEMATIC REVIEW; DERMATITIS, ATOPIC; METHODOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX; STANDARD; STANDARDS;

DERMATITIS, ATOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE STANDARDS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC;

EID: 84973409781     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.09.062     Document Type: Article

References (37)

1. 1 Schmitt, J., Langan, S., Williams, H.C., European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review. J All Clin Immunol 120 (2007), 1389–1398.
2. 2 Rehal, B., Armstrong, A.W., Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010. PLoS One, 6, 2011, e17520.
3. 3 Barbier, N., Paul, C., Luger, T., et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials program. Br J Dermatol 150 (2004), 96–102.
4. 4 Streiner, D.L., Norman, G.R., Cairney, J., Health measurement scales: a practical guide to their development and use. 2014, Oxford University Press, Oxford, United Kingdom.
5. 5 US Food and Drug Administration/Center for Drug Evaluation and Research. 2010, Draft guidance on calcipotriene, Washington, DC.
6. 6 US Food and Drug Administration/Center for Drug Evaluation and Research. 2010, Draft guidance on pimecrolimus, Washington, DC.
7. 7 Nankervis, H., Maplethorpe, A., Williams, H.C., Mapping randomized controlled trials of treatments for eczema–the GREAT database (the Global Resource of EczemA Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010). BMC Dermatol, 11, 2011, 10.
8. 8 Abramovits, W., Oquendo, M., Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. Skinmed 8 (2010), 72–79.
9. 9 Bangert, C., Strober, B.E., Cork, M., et al. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial. Dermatology 222:1 (2011), 36–48.
10. 10 Bieber, T., Vick, K., Fölster-Holst, R., et al. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy 62 (2007), 184–189.
11. 11 Bissonnette, R., Chen, G., Bolduc, C., et al. Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. Arch Dermatol 146 (2010), 446–449.
12. 12 Chapman, M.S., Schachner, L.A., Breneman, D., et al. Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis. J Am Acad Dermatol 53:Suppl (2005), S177–S185.
13. 13 Del Rosso, J.Q., Bhambri, S., Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis. J Clin Aesthet Dermatol 2 (2009), 24–32.
14. 14 Eichenfield, L.F., Lucky, A.W., Boguniewicz, M., et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. [see comment] J Am Acad Dermatol 46 (2002), 495–504.
15. 15 Fowler, J., Johnson, A., Chen, M., Abrams, K., Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis 79 (2007), 65–72.
16. 16 Frankel, A., Sohn, A., Patel, R.V., Lebwohl, M., Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis. J Drugs Dermatol 10:6 (2011), 666–672.
17. 17 Gollnick, H., Kaufmann, R., Stough, D., et al. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. Br J Dermatol 158 (2008), 1083–1093.
18. 18 Ho, V.C., Gupta, A., Kaufmann, R., et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 142 (2003), 155–162.
19. 19 Kaufmann, R., Bieber, T., Helgesen, A.L., et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 61 (2006), 375–381.
20. 20 Kaufmann, R., Folster-Holst, R., Hoger, P., et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J Allergy Clin Immunol 114 (2004), 1183–1188.
21. 21 Kempers, S., Boguniewicz, M., Carter, E., et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol 51 (2004), 515–525.
22. 22 Marini, A., Reinelt, K., Krutmann, J., Bilstein, A., Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomized, comparator-controlled, intra-individual double-blind, multi-center trial. Skin Pharmacol Physiol 27 (2014), 57–65.
23. 23 Mayser, P., Kupfer, J., Nemetz, D., et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream–results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 19 (2006), 153–158.
24. 24 Patrizi, A., Raone, B., Raboni, R., Neri, I., Efficacy and tolerability of a cream containing AR-GG27(R) (sorbityl furfural palmitate) in the treatment of mild/moderate childhood atopic dermatitis associated with pityriasis alba. A double-blind, placebo-controlled clinical trial. G Ital Dermatol Venereol 147 (2012), 1–8.
25. 25 Peserico, A., Stadtler, G., Sebastian, M., Fernandez, R.S., Vick, K., Bieber, T., Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicenter, randomized, double-blind, controlled study. Br J Dermatol 158 (2008), 801–807.
26. 26 Ruer-Mulard, M., Aberer, W., Gunstone, A., et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol 26 (2009), 551–558.
27. 27 Sigurgeirsson, B., Ho, V., Ferrandiz, C., et al. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of pediatric atopic dermatitis. J Eur Acad Dermatol Venereol 22 (2008), 1290–1301.
28. 28 Thaci, D., Reitamo, S., Gonzalez Ensenat, M.A., et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicenter, comparative study. Br J Dermatol 159 (2008), 1348–1356.
29. 29 Wahn, U., Bos, J.D., Goodfield, M., et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics, 110, 2002, e2.
30. 30 Wolff, K., Fleming, C., Hanifin, J., et al. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 152 (2005), 1296–1303.
31. 31 Wollenberg, A., Reitamo, S., Atzori, F., et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 63:6 (2008), 742–750.
32. 32 Spuls, P.I., Lecluse, L.L., Poulsen, M.L., Bos, J.D., Stern, R.S., Nijsten, T., How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol 130 (2010), 933–943.
33. 33 Schmitt, J., Langan, S., Stamm, T., Williams, H.C., Harmonizing Outcome Measurements in Eczema Delphi Panel. Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Invest Dermatol 131 (2011), 623–630.
34. 34 Charman, C.R., Venn, A.J., Williams, H., Measuring atopic eczema severity visually: which variables are most important to patients?. Arch Dermatol 141 (2005), 1146–1151.
35. 35 Norman, G., Likert scales, levels of measurement and the “laws” of statistics. Adv Health Sci Educ Theory Pract 15 (2010), 625–632.
36. 36 Busner, J., Targum, S.D., The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 4 (2007), 28–37.
37. 37 Williams, H.C., Gilchrest, B.A., Clinical trials submitted to the JID: place your bet and show us your hand. J Invest Dermatol 135 (2015), 325–327.